|Previous Section||Index||Home Page|
The Minister of State, Department of Health (Mr. John Denham): I congratulate my hon. Friend the Member for Burton (Mrs. Dean) on obtaining the debate and selecting this subject. It gives me an opportunity to say something about the Government's position in regard to treatment of lupus.
I am aware of the valuable work that my hon. Friend does in the all-party group that was formed in November 2000. I now know--which I did not before tonight--of her personal family experiences, of which she spoke movingly.
I, too, want to put on record a recognition of the contribution made by the voluntary sector in supporting people with lupus. The work of Lupus UK and its regional network is important. I hope that this year's lupus awareness week will build on the success of last year's event and succeed in its aim of raising public awareness of this distressing condition.
Lupus can occur at any age, and in either sex, although it is nine times more frequent among adult females than among adult males. The symptoms of the disease, though, are the same in men and women. Among children, lupus occurs three times more commonly in females than in males. Nine out of 10 patients with lupus are female. It is usually triggered between the ages of 15 and 50. The best estimate is that there are about 50,000 people with lupus in the UK, as my hon. Friend said.
Lupus is a chronic debilitating disorder of the immune system which is incurable and painful. Symptoms can range through the whole medical textbook, but certain symptoms predominate, such as joint pains and swelling, fever and skin rashes.
Lupus is one of the many diseases whose cause is not known. There is probably a genetic predisposition, although episodes can be triggered by environmental agents--for example, infections. Despite years of research, no virus or infectious cause can be identified; nor is there evidence of an environmental cause. Whatever the trigger, the basic problem is an alteration in the immune system. The normal immune system makes antibodies directed against the patient's own body, and this causes tissue damage.
Diagnosis of the disease is difficult because, as my hon. Friend said, many lupus symptoms mimic other illnesses, such as rheumatoid arthritis. There is no single laboratory test that can determine whether a person has lupus. Normally, diagnosis is made by a careful review of a person's entire medical history, together with an analysis of results obtained from laboratory tests and some specialised tests related to immune status. As my hon. Friend rightly said, that does not mean that nothing can be done to help patients with lupus. In the majority of patients, it can be controlled. Treatment aims to suppress the overactive immune system and diminish inflammation.
Treatment may initially be aggressive, perhaps involving the use of steroids, but often milder drugs, such as antimalarials, can be used later. With time, the aim is to treat the disease and use drugs that produce the fewest side effects. Patients may experience a fluctuating course of lupus, but most remain quite well and live at home rather than going into hospital.
I have already mentioned that lupus has no cure at present, that its cause is not fully understood and that diagnosis is often very difficult. That is why it is important to improve our understanding of how to treat and manage it by research. I am pleased to say that the Government, through our support for the Medical Research Council and other research streams, are helping in the drive to understand the causes.
In England, the main Government agency for research into the causes of and treatments for disease is the Medical Research Council, which receives its funding via the Department of Trade and Industry. We keep our priorities for research under review. In the NHS, priorities are identified through widespread consultation with
It has long been a principle that Governments do not prescribe to research councils how they should distribute resources. That is best decided by research and research users. The Medical Research Council takes all those factors into account.
The current edition of the national research register--issue 1, 2001--shows that there are 73 on-going projects, with another 95 recently completed, considering various aspects of lupus. The NHS helps all the projects by paying the hospital support costs of the units involved.
My hon. Friend mentioned the lupus research unit at St. Thomas's hospital. It is open to lupus patients from all corners of the United Kingdom, and runs special clinics each weekday, with dedicated staff who are trained in all aspects of lupus and related diseases. In addition to medical clinics, the unit has nurse-led clinics and make-up clinics. It provides patient advice services, including weekly lupus pregnancy counselling clinics, information booklets, a CD-ROM, and a hotline telephone service for patients and doctors. The unit now has the largest number of lupus patients on register in the world.
The unit is fully committed to treating this condition. Led by Dr. Graham Hughes, it undertakes research, supported by the St. Thomas's lupus trust. This research is world renowned and has already made major contributions to the understanding and treatment of this devastating illness. Last year, at the annual scientific meeting of the American college of rheumatology, the lupus unit was awarded first prize for a collaborative study with a unit in Milan. The research unit is clearly doing vital work in increasing our understanding of this complex illness. My hon. Friend the Minister for Public Health attended the launch of the Hughes syndrome foundation in February of this year.
My hon. Friend the Member for Burton mentioned a couple of specific issues. She spoke about the training of doctors and the provision of consultants. My understanding is that training and awareness of lupus should be part of the core training of doctors which is reviewed regularly with the royal medical colleges and the medical schools and universities. There is no evidence of a shortage of consultants in this area. If she has concerns that she wishes to write to me about, I shall be happy to look into the matter further, but that is my understanding of the position.
Entitlement to help with prescription charges is based on the principle that those who can afford to contribute should do so while those who are likely to have difficulty in paying should be protected. For example, children under 16 and people aged 60 or over are entitled to free NHS prescriptions. As my hon. Friend recognised, people suffering from certain medical conditions are also exempt from prescription charges.
NHS charges and all other aspects of Government spending were reviewed in 1998 as part of the Government's comprehensive spending review. Following that review, the Government made the commitment that all current prescription charge exemptions would be protected
The list of medical conditions conferring prescription charge exemption was introduced in 1968 after being agreed with the medical profession. The list has been reviewed on a number of occasions, but no clear-cut case for extending it has since emerged or attracted consensus.
When the medical exemptions were introduced, only 42 per cent. of all NHS prescriptions were dispensed free of charge. Now the figure is more than 85 per cent. As a result, many people with medical conditions not on the exempt list already get free prescriptions on other grounds.
We do sympathise with people who require regular or extensive medication, such as those with lupus, but we have no plans to extend the list of medical conditions that confer exemption from prescription charges. People who have to pay prescription charges can seek help under the NHS low-income scheme or through the purchase of a prescription prepayment certificate that offers considerable savings to those who need regular medication.
One of the aspects of lupus is the pain involved. Pain is a major problem and a common consequence of ill health; indeed, it is a major cause of ill health. It is important that good quality pain management be provided to patients to improve their health care and quality of life. We are committed to providing equity of access to health care and to reducing variations in the availability of services. Patients who suffer pain should have access to services that provide management programmes of proven effectiveness. In reviewing local provision, account should be taken of the needs of adults and children and should include patients with acute pain resulting from sudden illness or accident, as well as post-operative and chronic pain, including lupus.
The clinical standards advisory group report has shown that many NHS trusts have developed excellent services, but we recognise that, in some places, more needs to be done to drive up standards. We expect the NHS to take full account of that report when reviewing local provision to meet the needs of both adults and children.
Lupus can, as I said, be managed by drug regimes and also by careful monitoring and a flexible treatment programme. Patients can learn to manage their condition through information, by pursuing daily routines and by resting regularly, thus reducing stress and pain. We know from research that self-management schemes for people with chronic long-term medical conditions can have beneficial effects, including improved health status and fewer hospital admissions. The "Saving Lives--Our Healthier Nation" White Paper signalled our intention, reaffirmed in the NHS plan, to introduce a programme to help such people to manage their own health better, with specialised support from health care professionals and other agencies.
A specialist taskforce, chaired by the chief medical officer, has been examining in detail how an expert patients programme might be designed and embedded within mainstream NHS activity. The taskforce has examined a wide range of issues, including the role of patients as experts in managing their chronic disease,
I understand that a drug called Aslera has recently been developed in the United States as a potential treatment for lupus. It is the first new drug to be developed for use in lupus treatment for about 40 years. However, it is at an early stage of development, with further trial evidence being required on both long-term clinical and cost effectiveness. I understand also that it may be submitted for European licensing in the next two years. It is envisaged that, once licensed, it would be recommended as treatment for severe cases of lupus and prescribed alongside existing drug therapy.
My right hon. friend the Secretary of State recently announced that we shall develop a national service framework for long-term conditions. We intend that that framework will be used to produce specific standards for treating long-term neurological conditions. It will also provide generic standards for people with long-term chronic conditions such as lupus. I hope that my hon. Friend the Member for Burton will agree that that is a positive step forward.
I hope that my hon. Friend will also agree that the Government are sympathetic to the needs of patients with lupus. We have supported research into the causes of the disease through the Medical Research Council, and we hope that the standards produced by the national service framework and the work on the development of an expert patient programme will help to improve services for people with lupus. Finally, as I said, I hope that lupus awareness week will prove to be a success.